PPIDT00033
Drug Information
| Name | Desmopressin |
|---|---|
| Sequence | CYFQNCPdRGNH₂ |
| DrugBank_ID | DB00035 |
| Type | small molecule |
| Indication | - Indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void (intranasal). - Indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region (intranasal/parenteral). - Indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5% or mild to moderate classic von Willebrand's Disease (Type I) with factor VIII levels greater than 5% during surgical procedures and postoperatively to maintain hemostasis (parenteral). |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Solution | Intramuscular; Intravenous; Subcutaneous |
4 mcg / mL
|
| Solution | Intravenous |
4 ug/1mL
|
| Spray | Nasal |
0.1 ug/1mL
|
| Liquid | Intramuscular; Intravenous; Subcutaneous |
4 mcg / mL
|
| Solution | Nasal |
0.1 mg / mL
|
| Aerosol, metered | Nasal |
10 mcg / act
|
| Solution | Nasal |
0.100 mg
|
| Solution | Intravenous |
400000 mcg
|
| Solution | Nasal; Respiratory (inhalation) |
8900000 mcg
|
| Injection | Intravenous |
4 ug/1mL
|
| Injection | Intravenous; Subcutaneous |
4 ug/1mL
|
| Injection | Intravenous; Subcutaneous |
40 ug/10mL
|
| Injection, solution | Intravenous; Subcutaneous |
4 ug/1mL
|
| Injection, solution | Intravenous; Subcutaneous |
40 ug/10mL
|
| Powder | Not applicable |
1 g/1g
|
| Solution | Nasal |
0.1 mg/1mL
|
| Spray | Nasal |
0.1 mg/1mL
|
| Spray | Nasal |
10 ug/1
|
| Spray | Nasal |
10 ug/0.1mL
|
| Tablet | Oral |
0.1 mg/1
|
| Tablet | Oral |
0.2 mg/1
|
| Tablet, orally disintegrating | Sublingual |
120 ug
|
| Tablet, orally disintegrating | Sublingual |
240 ug
|
| Tablet, orally disintegrating | Sublingual |
60 ug
|
| Spray, metered | Nasal |
10 mcg / act
|
| Tablet | — |
|
| Tablet | — |
120 MICROGRAMMI
|
| Tablet | — |
240 MICROGRAMMI
|
| Tablet | — |
60 MICROGRAMMI
|
| Spray | Nasal |
0.001
|
| Solution | Sublingual |
0.4 mg
|
| Solution | Intrasinal; Nasal |
0.1 mg
|
| Injection, solution | Intravenous; Subcutaneous |
40 mcg
|
| Injection, solution | Parenteral |
20 MCG/1ML
|
| Injection, solution | Parenteral |
4 MCG/0.5ML
|
| Solution | Intramuscular; Intravenous; Subcutaneous |
20 cg
|
| Solution | Intramuscular; Intravenous; Subcutaneous |
400000 mcg
|
| Tablet, orally disintegrating | Oral |
120 cg
|
| Tablet, soluble | Oral |
|
| Solution | Intrasinal; Nasal |
10 mg
|
| Solution | Intrasinal; Nasal |
1000000 mg
|
| Solution | Intramuscular; Intravenous; Subcutaneous |
4 cg
|
| Solution | Intravenous; Subcutaneous |
0.025 mg
|
| Solution | Nasal |
89 mcg
|
| Solution | Parenteral |
15.000 mcg
|
| Tablet | Oral |
89 mcg
|
| Injection, solution | Intramuscular; Intravenous |
4 ug
|
| Solution | Nasal |
|
| Solution | — |
100 mcg/1ml
|
| Injection, solution | — |
4 mcg/1ml
|
| Spray | Nasal |
100 mcg/1ml
|
| Solution | Nasal; Respiratory (inhalation) |
0.089 mg
|
| Injection, solution | Intramuscular; Intravenous |
4 mcg/ml
|
| Injection | Intramuscular; Intravenous; Subcutaneous |
4 mcg/ml
|
| Injection | Intravenous |
|
| Tablet | Oral |
60 mcg
|
| Tablet | Oral |
120 mcg
|
| Powder | Oral |
120 cg
|
| Powder | Oral |
120 ug
|
| — | Oral |
|
| Powder | Oral |
240 ug
|
| Powder | Oral |
60 ug
|
| Spray | Nasal |
0.1 mg/ml
|
| Solution | Nasal |
0.1 mg/ml
|
| Tablet, orally disintegrating | Sublingual |
120 mcg
|
| Tablet, orally disintegrating | Sublingual |
240 mcg
|
| Tablet, orally disintegrating | Sublingual |
60 mcg
|
| Tablet, orally disintegrating | Sublingual |
|
| Tablet | Oral |
0.1 mg
|
| Tablet | Oral |
|
| Tablet | Oral |
0.2 mg
|
| Tablet | — |
100 mcg
|
| Tablet | — |
200 mcg
|
| Injection, solution | — |
4 MCG/ML
|
| Solution / drops | Nasal |
0.1 MG/ML
|
| Spray | Nasal |
50 MCG/ML
|
| Tablet | — |
0.1 MG
|
| Tablet | — |
0.2 MG
|
| Tablet | — |
120 MCG
|
| Tablet | — |
240 MCG
|
| Tablet | — |
60 MCG
|
| Solution | Nasal |
0.09 mg
|
| Solution | Oral |
|
| Aerosol | Nasal |
89.000 mg
|
| Solution | Parenteral |
13.400 mcg
|
| Tablet | Oral |
178.000 mcg
|
| Tablet | Sublingual |
27.7 ug/1
|
| Tablet | Sublingual |
55.3 ug/1
|
| Tablet, orally disintegrating | Sublingual |
25 mcg
|
| Tablet, orally disintegrating | Sublingual |
50 mcg
|
| Powder | Oral |
25 mcg
|
| Powder | Oral |
|
| Powder | Oral |
50 mcg
|
| Spray, metered | Nasal |
0.83 ug/1
|
| Spray, metered | Nasal |
1.66 ug/1
|
| Solution | Nasal |
89.000 mcg
|
| Tablet, orally disintegrating | Sublingual |
120 Mikrogramm
|
| Tablet, orally disintegrating | Sublingual |
240 Mikrogramm
|
| Tablet, orally disintegrating | Sublingual |
60 Mikrogramm
|
| Spray, metered | Nasal |
0.1 g / L
|
| Solution | Parenteral |
30.0 mcg
|
| Solution | Intravenous; Subcutaneous |
1500000 mcg
|
| Spray | Nasal |
1.5 mg/ml
|
| Solution | Intravenous; Subcutaneous |
15 ug/ml
|
| Injection, solution | Intravenous; Subcutaneous |
|
| Injection, solution | Intravenous; Subcutaneous |
15 mcg/ml
|
| Solution | Intravenous; Subcutaneous |
15 mcg / mL
|
| Spray | Nasal |
150 mcg / act
|
| Solution | Nasal |
89.00 mcg
|
| Spray | Nasal |
|
| Spray, metered | Nasal |
0.1 mg/ml
|
| Solution | — |
89.00 mcg
|
| Tablet | Sublingual |
120 mcg
|
| Tablet | Sublingual |
60 mcg
|
| Solution | Intravenous |
15.000 mcg
|
| Spray, metered | Nasal |
1.5 mg/1mL
|
| Solution / drops | Nasal |
100 mcg/1ml
|
| Injection, solution | — |
15 mcg/1ml
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P30559 | OXTR | Oxytocin receptor | Homo sapiens | agonist | Link |
| target | P30518 | AVPR2 | Vasopressin V2 receptor | Homo sapiens | agonist | Link |
| target | P37288 | AVPR1A | Vasopressin V1a receptor | Homo sapiens | agonist | Link |
| target | P47901 | AVPR1B | Vasopressin V1b receptor | Homo sapiens | agonist | Link |
| enzyme | P35354 | PTGS2 | Prostaglandin G/H synthase 2 | Homo sapiens | inducer | Link |
| enzyme | P23219 | PTGS1 | Prostaglandin G/H synthase 1 | Homo sapiens | inducer | Link |